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Abstract
Background: Reversible interactions between the components of cellular signaling pathways allow for
the formation and dissociation of multimolecular complexes with spatial and temporal resolution and, thus,
are an important means of integrating multiple signals into a coordinated cellular response. Several
mechanisms that underlie these interactions have been identified, including the recognition of specific
docking sites, termed a D-domain and FXFP motif, on proteins that bind mitogen-activated protein kinases
(MAPKs). We recently found that phosphatidylinositol-specific phospholipase C-γ1 (PLC-γ1) directly binds
to extracellular signal-regulated kinase 2 (ERK2), a MAPK, via a D-domain-dependent mechanism. In
addition, we identified D-domain sequences in several other PLC isozymes. In the present studies we
sought to determine whether MAPK docking sequences could be recognized in other enzymes that
metabolize phosphatidylinositols (PIs), as well as in enzymes that metabolize inositol phosphates (IPs).
Results: We found that several, but not all, of these enzymes contain identifiable D-domain sequences.
Further, we found a high degree of conservation of these sequences and their location in human and mouse
proteins; notable exceptions were PI 3-kinase C2-γ, PI 4-kinase type IIβ, and inositol polyphosphate 1-
phosphatase.
Conclusion: The results indicate that there may be extensive crosstalk between MAPK signaling and
signaling pathways that are regulated by cellular levels of PIs or IPs.
Background
MAPKs catalyze the transfer of the γ-phosphate of adeno-
sine triphosphate (ATP) to serine (S) or threonine (T) res-
idues that precede proline (P) [1,2]; thus, these enzymes
are termed proline-directed serine/threonine kinases.
Although the sequences ST and TP are sufficient for phos-
phorylation to occur, the optimal sequence for phospho-
rylation by a MAPK is PX(S/T)P [1,3]. The majority of
cellular proteins contain an SP or a TP sequence, yet,
many of these proteins are not MAPK substrates [4], indi-
cating that a mechanism exists for achieving substrate spe-
cificity for the MAPKs. This specificity is conferred by the
substrate through a docking domain. In addition to
underlying specificity, these docking interactions increase
the catalytic efficiency of substrate phosphorylation [5-7].
MAPK docking sites
A MAPK docking site, distinct from the phosphoacceptor
site, was first identified in c-Jun [8,9], a c-Jun N-terminal
kinase (JNK) substrate; this site was designated the "δ
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domain". Subsequently, a JNK binding site in the tran-
scription factor ATF-2 [10,11] and a motif termed the "d-
box" of Elk-1 that binds ERK2 [4,12] were noted to be
similar in sequence to the JNK binding site in c-Jun.
Related motifs have been identified in a number of other
proteins and have been given various names, including
DEJL (docking sites for ERK and JNK, LXL) domain [4],
kinase interaction motif (KIM) [13,14], MAPK-docking
site [15,16], D box [5,12], D-site [17] and D-domain
[6,18-20]. It is important to note that, although these
domains were identified based on the ability to bind one
or more MAPK, there are differences in the consensus
sequences used to identify each of them. For example,
MacKenzie et al. [14] proposed a consensus KIM sequence
of (V/L)X2(R/K)(R/K)X(3–6)L, with V, L, R, and K repre-
senting the amino acids valine, leucine, arginine and
lysine, respectively; Bardwell et al. [16] define a consensus
MAPK-binding site sequence of (R/K)2X(2–6)(L/I)X(L/I),
with I representing the amino acid isoleucine; and Korn-
feld and colleagues [4] reported two consensus sequences
for the DEJL domain: (K/R)X(X/K/R)(K/R)X(1–4)(L/I)X(L/
I) and (K/R)(K/R)(K/R)X(1–5)(L/I)X(L/I). In the present
studies we use the term D-domain and the consensus
sequences reported by Kornfeld and colleagues [4].
Sharrocks and colleagues [21] report that D-domains are
characterized by a cluster of basic residues positioned
amino-terminal to an (L/I)X(L/I) motif followed by a tri-
plet of hydrophobic amino acids that precedes a series of
proline residues [17,21]. These investigators assessed the
role of each of these regions in the binding of ERK2 and
p38 to transcription factors, MEF2A, SAP-1, and Elk-1.
They determined that mutation of the basic region of the
transcription factors reduced their phosphorylation by
both phospho-ERK2 and phospho-p38 [21]. This suggests
that the basic residues are important for both ERK2 and
p38 targeting of MAPK substrates. Mutation of the (L/
I)X(L/I) motif (also called the LXL motif) diminished
phosphorylation of phospho-ERK substrates, whereas it is
not required for phosphorylation of substrates by the
MAPK, phospho-p38 [21]. It was also determined that the
hydrophobic patch plays an important role in phosphor-
ylation of the substrates by both phospho-ERK and phos-
pho-p38; however, this patch is more important for p38
binding than ERK2 binding. Barsyte-Lovejoy et al. [21]
concluded that the proline residues were not important in
specificity determination of MAPK substrates. Therefore,
the authors hypothesize that the proline residues may
play a structural role within the motif.
D-domains can show specificity for families of MAPKs; for
example, the Elk-1 D-domain binds JNK and ERK, but not
p38 [5,22]; both the SAP-1 and Elk-1 D-domains bind
ERK2, whereas the SAP-1, but not Elk-1, D-domain binds
p38α [22]. Other D-domains show specificity within a
MAPK family; for example, the SAP-1 D-domain binds
p38α and p38β, but not p38δ [22]. The D-domain can be
positioned either N- or C-terminal to the phosphorylation
site [7,12,16,19,23].
A second MAPK docking motif has also been identified:
the FXFP motif, or DEF (docking site for ERK, FXFP) motif
[4,18,22], where F and P represent the amino acids pheny-
lalanine and proline, respectively. Binding and substrate
phosphorylation can occur in the absence of the proline
residue [14,18]; however, its presence does increase the
effectiveness of the motif [18]. Thus, we chose to include
the proline in our searches. The identity of the second (X)
residue is highly variable [4,18]. In most, if not all, pro-
teins, the FXFP motif is C-terminal to the phosphorylation
site [4,18,19,24]. In general, it appears that the FXFP motif
occurs more proximal to a phosphorylation site than is
often the case for a D-domain [4,18,20,22,24]. The FXFP
motif binds ERK2 and p38α [18,22], but not JNK3 [4] and
p38β [4,22]. The FXFP motif and D-domain are each suf-
ficient for MAPK docking; however, when both are
present in a protein, they function additively [18,22].
We recently identified a D-domain sequence in PLC-γ1
and provided strong evidence that this sequence mediated
an observed interaction between PLC-γ1 and phospho-
ERK2 [25]. We have also reported that PLC-γ2, -β1, -β2,
and -β4 each have at least one identifiable D-domain, as
well co-immunoprecipitate with ERK2 [26]. Based on
these observations, we have proposed that MAPK signal-
ing and the metabolism of PIs are integrated. In order to
substantiate this hypothesis, we sought to determine
whether MAPK docking sites could be recognized in other
enzymes that metabolize PIs; additionally, we sought sup-
port for extending this hypothesis to include the metabo-
lism of IPs.
Overview of phosphatidylinositol and inositol phosphate 
metabolism and signaling
Eight PIs and more than 20 IPs have been identified [27-
30]. Several reviews of the metabolism and cellular roles
of these molecules have appeared [27-35]. As the physio-
logic functions of the PIs and IPs were not a primary focus
of the present studies, we will not summarize this infor-
mation here; instead, the interested reader is directed to
the sources cited above; we acknowledge that this is only
a partial listing of the reviews that have been written on
these subjects. PIs are substrates for a variety of phosphol-
ipases, acyl transferases, kinases and phosphatases, while
IPs are metabolized by a series of kinases and phos-
phatases. Of these enzymes, we have limited the scope of
the present studies to kinases and phosphatases. In order
to assist the reader in understanding the reactions cata-
lyzed by the enzymes which we analyzed, the pathways
for the metabolism of PIs and IPs by various kinases andCell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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phosphatases are shown in Figures 1A and 1B, respec-
tively. We use the IUPAC-IUB nomenclature for the iden-
tification of phosphatidylinositol (PtdIns) and inositol
(Ins) phosphates (P): numbers are used to designate the
carbon atoms to which phosphate groups are bound and
the total number of phosphate groups is designated by a
subscript, with the exception that no subscript is
employed to designate the presence of a single phosphate
group. For example, phosphatidylinositol 4-phosphate is
designated PtdIns4P and inositol 1,4,5-trisphosphate is
designated Ins(1,4,5)P3. For a review of inositol phos-
phate chemistry the reader is referred to recent articles by
Shears [36] and Irvine [37].
Results and discussion
Search strategy
We obtained the primary sequences of human and mouse
kinases and phosphatases that control the phosphoryla-
A: Pathways of metabolism of phosphatidylinositols in animals. B: Pathways of inositol phosphate metabolism Figure 1
A: Pathways of metabolism of phosphatidylinositols in animals. This figure is based on similar figures in Toker [28] 
and Parker [29] and information provided in the Results and Discussion section. We are not aware of evidence that PtdIns5P is 
a substrate for a PI 3-kinase, producing PtdIns(3,5)P2; therefore, an arrow has not been included for this reaction.
B: Pathways of inositol phosphate metabolism. The pathways of the metabolism of inositol phosphates in animal cells 
are shown; additional pathways are present in plants and slime mold [30]. The PLC-catalyzed synthesis of 1,2-diacylglycerol 
(1,2-DAG) and Ins(1,4,5)P3 is also shown. The figure is based on similar figures found in Irvine and Schell [30], Shears [36], and 
Irvine [37], as well as information provided in the Results and Discussion section.Cell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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Table 1: Kinases (human) that have an FXFP motif and/or D-domain sequence. The number of potential MAPK phosphorylation sites, 
sequences fitting the optimal MAPK phosphorylation consensus sequence of PX(S/T)P, and FXFP motifs and D-domain sequences in 
kinases that use phosphatidylinositols or inositols as substrates are listed in the table; all sequences are for human proteins.
Isozyme GenBank 
Accession #
# amino 
acids
number of (S/
T)P sites
Site(s) with the consensus 
PX(S/T)P sequence
FXFP 
motif
D-domain motif
PI 3-kinase
Class I
PI 3-kinase α P42336 1068 6 none none 271KYIRSCIML
398RAARLCLSI
PI 3-kinase γ P48736 1101 13 none none 806KKKPLWL
PI 3-kinase δ NP_005017 1044 4 none 585FSFP none
Class II
PI 3-kinase C2-α NP_002636 1686 16 118PVTP
199PLTP
202PATP
none 238KNGKARTDLEI
PI 3-kinase, C2-γ CAA03853 1448 9 none none 400KVSRQCLLTL
830KEQKLIKI
1327KKPKVQLVI
1347KHMKNIHL
Class III
PI 3-kinase Vps34-type S57219 887 6 none none 656KLLRKENLDL
PI 4-kinase
PI 4-kinase α (PI4K230) P42356 2044 16 215PSSP
590PPSP
1822FVF
P
15RRRDAVIAL
15RRRDAVIALGI
1340KRLREDISI
1340KRLREDISIMI
1429KRRTLLL
1429KRRTLLLSL
PI 4-kinase β (PI4K92) NP_002642 828 7 none none 244RGTKLRKLIL
360KTQRLISELSL
608KPYKILVI
PI 4-kinase type II (PI4K55) NP_060895 479 5 49PGSP none 435KDNKSPLHL
PI 4-kinase type II-β (PI4K55) NP_060793 481 3 none none 239KVGRKFHRIGL
PIP kinase
Type I PIPK (PI4P 5-kinase)
PI4P 5-kinase, type Iα NO_003548 549 3 501PQTP none 376RNSKGERLLL
379KGERLLLYI
379KGERLLLYIGI
PI4P 5-kinase, type Iβ NP_003549 540 4 464PSTP none 335KSHRGEKLLL
PI4P 5-kinase type Iγ NP_036530 668 6 510PCTP none 386RGERLLLHI
386RGERLLLHIGI
Type III PIPK (PIKfyve; PI3P 5-kinase)
PIKfyve Q9Y2I7 2098 32 18PRSP
21PTSP
32PLTP
251PRTP
581PFTP
1524PPSP
none 259KASRNIFL
700KNPKILLL
1981KMVRDNPLYI
Ins(1,4,5)P3 3-kinase
Ins(1,4,5)P3 3-kinase B P27987 946 24 69PRSP
164PRSP
262PASP
56FLFP 665KKKYPWIQL
Ins(1,3,4,5,6)5 2-kinase
Ins(1,3,4,5,6)5 2-kinase AAM75353 491 5 none 240FFFP noneCell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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tion state of the inositol ring in PIs and IPs from GenBank
at NCBI and searched these sequences for an FXFP motif
and the two consensus sequences for a D-domain
reported by Kornfeld and colleagues [4]: (K/R)X(X/K/
R)(K/R)X(1–4)(L/I)X(L/I) or (K/R)(K/R)(K/R)X(1–5)(L/
I)X(L/I). We note that this strategy most likely failed to
identify all possible sequences that may function as MAPK
docking sites. For example, both the human and mouse
Class I PI 3-kinase β include the sequence LILRRHGNLFI,
which contains a KIM, as defined by MacKenzie et al [16],
and a MAPK-docking site, as defined by Bardwell et al.
[16], but not a D-domain according to the criteria that we
employed. Similarly, the human and mouse Ins(1,3,4)P3
5/6-kinase/Ins(3,4,5,6) 1-kinase contain the sequence
LCRKRGXEVVQLNL (X is M in human and I in mouse),
which fits the consensus sequences for a KIM and a MAPK-
binding site, but not a D-domain. We chose to use the cri-
teria of Kornfeld and colleagues based on its successful
application in the identification of D-domains in PLC iso-
zymes [25,26]. Although the list that we have compiled is
likely to be incomplete, it does serve as a useful first
approximation. We also searched each of the enzyme
sequences for potential MAPK phosphorylation sites (i.e.,
(S/T)P sequences) and MAPK optimal phosphorylation
sequences, PX(S/T)P. Finally, we note that we did not ana-
lyze the sequences of enzymes that control the metabo-
lism of the diphosphorylated IPs.
Presentation of the data
In order to facilitate the presentation of the data, we sepa-
rated human from mouse enzymes, kinases from phos-
phatases, and enzymes in which we identified a D-
domain and/or FXFP motif from those in which we did
not. Human and mouse kinases having a D-domain and/
or FXFP motif are contained in Tables 1 and 3, respec-
tively, whereas human and mouse kinases that do not
have either of these sequences are presented in Tables 2
and 4, respectively. Similarly, human and mouse phos-
phatases containing a D-domain and/or FXFP motif are
listed in Tables 6 and 8, respectively, while human and
mouse phosphatases that are devoid of these sequences
are contained in Tables 7 and 9, respectively.
In the following discussion we use the terms "alternative
pair" and "overlapping" in referring to relationships of D-
domains. An alternative pair of D-domains has the same
amino-terminus and two possible carboxyl-termini: e.g.,
15RRRDAVIAL and 15RRRDAVIALGI in human PI 4-
kinase α (Table 1). We use the term overlapping to iden-
tify D-domains that have distinct amino-termini and car-
boxyl-termini, but share a region of sequence: e.g.,
376RNSKGERLLL and 379KGERLLLYI found in human
PI4P 5-kinase type Iα (Table 1).
PI 3-kinase
Phosphatidylinositol 3-kinase (also called phosphoi-
nositide 3-kinase, PtdIns 3-kinase, PI 3-kinase, and PI3K)
isozymes catalyze the phosphorylation of the 3-position
of the inositol ring of phosphatidylinositols [32]. Three
classes (I, II, and III) of PI 3-kinase have been identified
[38,39]. These classes are differentiated on the basis of
their subunit composition, substrate specificity and mech-
anisms of regulation. The Class I enzymes are heterodim-
ers of a regulatory subunit, of various sizes, and a catalytic
subunit of approximately 110 kDa. Three distinct forms of
the catalytic subunit (p110α, p110β, and p110δ) and five
forms of the regulatory subunit (p85α, p85β, p55α, p55γ,
and p50α) have been identified. The class IB isoform con-
sists of a p101 regulatory subunit coupled to a p100γ cat-
alytic subunit. Class I enzymes catalyze the synthesis of
PtdIns3P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3  [40,41];
PtdIns(4,5)P2 may be the preferred substrate in vivo [42].
Table 2: Kinases (human) that do not have an FXFP motif and/or D-domain sequence. Kinases that use phosphatidylinositols or 
inositols as substrates and do not contain an FXFP or D-domain sequence are listed in the table; all sequences are for human proteins. 
The number of potential MAPK phosphorylation sites and sequences fitting the optimal MAPK phosphorylation in these kinases are 
also identified.
Isozyme GenBank 
Accession #
# amino acids number of 
(S/T)P sites
Site(s) with the consensus 
PX(S/T)P sequence
PI 3-kinase β NP_006210 1070 3 none
PI 3-kinase, C2-β O00750 1634 17 none
PIP kinase Type IIα NP_005019 406 5 314PDSP
PIP kinase Type Iiβ P78356 416 4 324PDSP
PIP kinase Type Iiγ NP_079055 421 1 none
Ins(1,4,5)P3 3-kinase A P23677 461 4 18PCSP
93PTSP
Ins(1,4,5)P3 3-kinase C NP_079470 683 8 334PETP
Ins(1,3,4)P3 5/6-kinase/Ins(3,4,5,6)P4 1-kinase NP_055031 414 3 none
Inositol polyphosphate multikinase/Ins(1,3,4,6)P4 5-kinase Q8NFU5 416 5 noneCell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
Page 6 of 18
(page number not for citation purposes)
Class II isozymes are monomeric catalytic subunits (α, β,
and γ) containing a carboxyl-terminal C2 domain; these
enzymes may be referred to as PI3K-C2. PtdIns and
PtdIns4P, and under certain conditions PtdIns(4,5)P2, are
substrates for the Class II PI 3-kinase [39,43]. A single
Class III isozyme, which is specific for PtdIns, has been
identified [44].
The Class I p110α and p110γ human (Table 1) and mouse
(Table 3) proteins contain D-domains, whereas the p110β
Table 3: Kinases (mouse) that have an FXFP motif and/or D-domain sequence. The number of potential MAPK phosphorylation sites, 
sequences fitting the optimal MAPK phosphorylation consensus sequence of PX(S/T)P, and FXFP motifs and D-domain sequences in 
kinases that use phosphatidylinositols or inositols as substrates are listed in the table; all sequences are for mouse proteins.
Isozyme GenBank 
Accession #
# amino acids # (S/T)P sites Site(s) with the consensus 
PX(S/T)P sequence
FXFP motif D-domain motif
PI 3-kinase
Class I
PI 3-kinase α NP_032865 1068 6 none none 271KYIRSCIML
398RLARLCLSI
PI 3-kinase γ NP_064668 1102 12 none none 807KKKPLWL
Class II
PI 3-kinase, C2-α NP_035213 1509 13 24PLTP
27PATP
1374PFSP
none 63KNGKARTDLEI
PI 3-kinase, C2-γ1 NP_997566 1506 12 none none 930KDIKTCHLPL
1409KHLKNIHL
PI 3-kinase, C2-γ2 NP_035214 653 3 none none 77KDIKTCHLPL
556KHLKNIHL
Class III
PI 3-kinase Vps34-type NP_852079 887 4 none none 656KLLRKENLDL
PI 4-kinase
PI 4-kinase α (PI4K230) NP_001001983 2044 16 215PSSP
590PPSP
1822FVFP 15RRRDAVIAL
15RRRDAVIALGI
1340KRLREDISI
1340KRLREDISIMI
1429KRRTLLL
1429KRRTLLLSL
PI 4-kinase β (PI4K92) NP_780565 801 8 none none 232RGTKLRKLIL
333KTQRLISELSL
581KPYKILVI
PI 4-kinase type II 
(PI4K55)
NP_663476 479 5 49PCSP none 435KDNKSPLHL
PIP kinase
Type I PIPK (PI4P 5-kinase)
PI4P 5-kinase, type Iα NP_032872 539 3 464PSTP none 335KSHRGEKLLL
PI4P 5-kinase type Iβ NP_032873 546 5 498PQTP none 374RNNKGERLLL
377KGERLLLYI
377KGERLLLYIGI
PI4P 5-kinase type Iγ NP_032870 661 5 509PCTP none 386RGERLLLHI
386RGERLLLHIGI
Type III PIPK (PIKfyve; PI3P 5-kinase)
PIKfyve NP_035216 2052 31 18PRSP
21PASP
32PLTP
262PRTP
536PFTP
1479PPSP
none 270KASRNIFL
655KNPKILLL
1935KMVRDNPLYICell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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(Tables 2 and 4) and p110δ (Tables 1 and 4) isozymes do
not. Of all the PI 3-kinase sequences that we analyzed,
only the human PI 3-kinase δ (Table 1) contains an FXFP
motif (585FSFP).
The Class II PI3-kinase C2-α contains a D-domain that is
conserved in the human (Table 1) and mouse (Table 3)
isozymes. PI 3-kinase C2-α was the only PI 3-kinase iso-
zyme in which we found an optimal MAPK phosphoryla-
tion sequence (Tables 1, 2, 3, 4). The human and mouse
PI 3-kinase C2-α proteins each contain three such
sequences; a sequence alignment revealed that two of
these (PLTP and PATP) are conserved, while the third,
118PVTP and 1374PFSP in human and mouse, respectively,
is unique. Both the human (Table 1) and mouse (Table 3)
PI 3-kinase C2-γ contain D-domains. A sequence align-
ment of these two proteins revealed that only the last D-
domain (1347KHMKNIHL in human and 1409KHLKNIHL
in mouse) aligns; all of the other identified D-domains are
unique to one or the other protein. These results indicate
the MAPK-dependent regulation of the human and mouse
Class II PI 3-kinases may be significantly different and,
thus, caution should be exercised when comparing studies
on these two proteins.
The human (Table 1) and mouse (Table 3) Class III PI 3-
kinase contains a conserved D-domain. Neither of these
proteins contains an FXFP motif or an optimal phosphor-
ylation sequence for MAPKs.
PI 4-kinase
Phosphatidylinositol 4-kinase (PtdIns 4-kinase, PI 4-
kinase) catalyzes the phosphorylation of PtdIns to pro-
duce PtdIns4P. Subfamilies (Types II and III; or PI4K230,
PI4K92 and PI4K55 using the nomenclature of Heilmeyer
et al. [45]) of PI 4-kinase have been identified; these pos-
ses a conserved C-terminal catalytic domain and diverse
N-terminal regulatory domains [45]. Differing physio-
logic functions have been ascribed to each of the three
subfamilies [45-49].
PI4Kα (also called PI 4-kinase 230) contains three alterna-
tive pairs of D-domains that are conserved in human
(Table 1) and mouse (Table 3) sequences. PI4Kα also con-
tains an FXFP sequence and two optimal MAPK phospho-
rylation sequences that are conserved in human and
mouse proteins. PI 4-kinase β (also called PI 4-kinase 92)
contains three D-domains that are conserved in the
human (Table 1) and mouse (Table 3) isozymes. The first
of these (232RGTKLRKLIL) overlaps with an identifiable
bipartite nuclear localization sequence motif [45]. The
human and mouse PI 4-kinase-β do not contain an FXFP
motif or optimal MAPK phosphorylation sequence. The
Table 4: Kinases (mouse) that do not have an FXFP motif and/or D-domain sequence. Kinases that use phosphatidylinositols or 
inositols as substrates and do not contain an FXFP or D-domain sequence are listed in the table; all sequences are for mouse proteins. 
The number of potential MAPK phosphorylation sites and sequences fitting the optimal MAPK phosphorylation in these kinases are 
also identified.
Isozyme GenBank Accession # # amino acids # (S/T)P sites Site(s) with the consensus 
PX(S/T)P sequence
PI 3-kinase β NP_083370 1064 4 none
PI 3-kinase δ NP_032866 1043 3 none
PI 4-kinase type II-β (PI4K55) NP_083020 445 2 none
PIP kinase Type Iiα NP_032871 405 4 314PDSP
PIP kinase Type Iiβ Q80XI4 416 3 324PDSP
PIP kinase Type Iiγ NP_473438 421 2 none
Ins(1,4,5)P3 3-kinase A Q8R071 459 5 18PCSP
92PASP
Ins(1,4,5)P3 3-kinase C NP_853624 678 8 328PETP
Ins(1,3,4)P3 5/6-kinase/Ins(3,4,5,6)P4 1-kinase NP_766172 419 4 none
Inositol polyphosphate multikinase/Ins(1,3,4,6)P4 5-kinase Q7TT16 396 2 none
Table 5: Reactions catalyzed by PIP kinases (based on [50] and 
[51])
Type I PIP kinase
PI → PI5P
PI3P → PI(3,4)P2
PI4P → PI(4,5)P2
PI3P → → PI(3,4,5)P3
PI(3,4)P2 → PI(3,4,5)P3
Type II PIP kinase
PI3P → PI(3,4,)P2
PI5P → PI(4,5)P2
PI3P → → PI(3,4,5)P3
Type III
PI → PI5P
PI3P → PI(3,5)P2Cell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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Table 6: Phosphatases (human) that have an FXFP motif and/or D-domain sequence. The number of potential MAPK phosphorylation 
sites, sequences fitting the optimal MAPK phosphorylation consensus sequence of PX(S/T)P, and FXFP motifs and D-domain 
sequences in phosphatases that use phosphatidylinositols or inositols as substrates are listed in the table; all sequences are for human 
proteins.
Isozyme GenBank 
Accession #
# amino 
acids
# (S/T)P 
sites
Site(s) with the 
consensus PX(S/T)P 
sequence
FXFP 
motif
D-domain motif
monophosphatase
inositol monophosphatase A1 NP_005527 277 2 none none 261RIAKEIQVIPL
1-phosphatase
Inositol polyphosphate 1-phosphatase P49441 399 1 none none 378RKRLETFLSL
3-phosphatase
Myotubularin-related protein 1 isoform 1; 
MTMR1-1
NP_003819 665 3 none none 177KDMRNLRL
Myotubularin-related protein 1 isoform 2; 
MTMR1-2
NP_789746 568 2 none none 177KDMRNLRL
PI(3,4,5)P3 3-phosphatase, PTEN P60484 403 2 none 241FEFP none
4-phosphatase
Inositol polyphosphate 4-phosphatase, Type Ia NP_004018 938 7 none none 147RHHRLHLTL
Inositol polyphosphate 4-phosphatase, Type Ib NP_001557 954 8 none none 147RHHRLHLTL
Inositol polyphosphate 4-phosphatase, Type Iα3 AAK58870 977 7 none none 147RHHRLHLTL
SAC1 poly-phosphatidylinositol phosphatase AAQH16559 587 3 none none 345KNMRWDRLSI
348RWDRLSILL
461RTGKRTHLGL
517RDWKFLAL
517RDWKFLALPI
5-phosphatase
Group II
Inositol polyphosphate 5-phosphatase OCRL-1 Q01968 901 3 none none 446RLLKFDQLNI
Inositol polyphosphate 5-phosphatase OCRL-2 NP_001578 893 3 none none 446RLLKFDQLNI
Synaptojanin 2 (synaptic inositol 1,4,5-
trisphosphate 5-phosphatase 2)
O15056 1496 17 987PVSP
1218PETP
1249PLSP
none 617RSHRYILL
Sac-domain-containing inositol phosphatase 2 
isoform 1; inositol polyphosphate 5-phosphatase 
F isoform 1
NP_055752 1132 12 259PETP none 85KVTKIAVLSL
Sac-domain-containing inositol phosphatase 3 NP_055660 907 5 none none 663KFHKYEEEIDI
Inositol polyphosphate 5-phosphatase, 75 kDa NP_005531 748 5 none none 31RQSRLLGL
335KYAKVKLIRL
340KLIRLVGIML
Inositol polyphosphate 5-phosphatase, 75 kDa; 
Inositol polyphosphate 5-phosphatase B
NP_032411 993 5 none none 31RQSRLLGL
420KFVRLVGIML
Group III
Inositol polyphosphate 5-phosphatase, 145 kDa; 
PI(3,4,5)P3 5-phosphatase; SH2-containing 
inositol 5'-phosphatase 1; SHIP1
NP_005532 1188 18 286PESP
960PPTP 968PISP
1133PPTP
none 348KSQKFLNKLVI
Group IV
PI polyphosphate 5-phosphatase type IV; Inositol 
polyphosphate 5-phosphatase E
AAF81404 644 10 55PATP 239PRSP none 79RLERALSL
596RPGRDNIPL
608KFDRELYL
608KFDRELYLLGICell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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human (Table 1) and mouse (Tabl3 3) PI 4-kinase type II
(also called PI 4-kinase 55) contain a conserved D-
domain and optimal phosphorylation sequence for a
MAPK. Neither protein contains an FXFP motif. The
human (Table 1), but not the mouse (Table 4), PI 4-
kinase type II-β contains a single D-domain, while neither
protein contains a sequence fitting the MAPK optimal
phosphorylation sequence or the FXFP motif.
PIP kinase
Phosphatidylinositol phosphate kinases (PIP kinases,
PIPKs) utilize PtdIns3P, PtdIns4P, and PtdIns5P as sub-
strates, catalyzing the synthesis of PtdIns(3,4)P2,
PtdIns(3,5)P2, and PtdIns(4,5)P2  (Table 5). These
enzymes are also able to catalyze the formation of
PtdIns5P and PtdIns(3,4,5)P3 (Table 5). Three types (I, II
and III) of PIP kinase are defined based on primary
sequence, substrate specificity, and subcellular localiza-
tion [51]. These families are often designated by the reac-
tion that they catalyze most efficiently. Thus, the Type I
PIP kinases are also termed PI4P 5-kinase, the Type II PIP
kinases are termed PI5P 4-kinases, and the Type III PIP
kinases are called PI3P 5-kinases. Three forms (termed α,
β, and γ), each with multiple splice variants, of Type I and
Type II PIP kinase have been identified [52-55]. It should
be noted that the nomenclature for the α- and β-forms of
the human and mouse Type I PIP kinase are reversed: that
is, the human Type Iα enzyme corresponds to the mouse
Type Iβ enzyme, and vice versa.
Each of the Type I isozymes contain at least one identifia-
ble D-domain that was conserved in humans and in mice.
In human PI4P 5-kinase Type Iα (Table 1) an alternative
pair of D-domains (379KGERLLLYI and 379KGERLLLYIGI)
overlaps with a different D-domain (376RNSKGERLLL).
This observation raises the intriguing possibility that these
sequences are specific for binding of a particular MAPK, or
MAPK family, and that there is competition among
MAPKs for binding, with the likelihood that a mecha-
nism(s) exists for the regulation of this binding. Further,
the MAPK that is bound may affect the kinetics of the sig-
nal that is generated and, thus, the downstream response.
The identified alternative pair of D-domains in PI4P 5-
kinase type Iγ (PIPKIγ) (Tables 1 and 3) may be responsi-
ble for binding phospho-ERK1, which has been shown to
catalyze the phosphorylation of serine 650 in PIPKIγ [56].
Phosphorylation of serine 650 inhibits the binding of
talin to PIPKIγ and may play a role in synaptic neurotrans-
mission and focal adhesion disassembly during mitosis.
None of the Type I PIP kinases that we analyzed contains
an FXFP motif (Tables 1 and 3). Each of the Type I PIPKs
that we analyzed contains an optimal MAPK phosphor-
ylation site that is conserved in human and mouse pro-
teins. In the case of PIPKIγ, this is not serine-650.
However, it is possible that other MAPKs are capable of
phosphorylating threonine-512 (human)/threonine-511
(mouse).
The Type II isozymes (Tables 2 and 4) were found to be
devoid of D-domain sequences and FXFP motifs. How-
ever, the Type IIα and Type IIβ isozymes do contain an
optimal MAPK phosphorylation sequence that is con-
served in human (Table 2) and mouse (Table 4) protein
sequences.
The PIKfyve human (Table 1) and mouse (Table 3)
sequences each contain six MAPK optimal phosphoryla-
tion sequences. This is the most that we found in any of
the sequences that we analyzed. These enzymes contain
three conserved D-domain sequences, but are devoid of
an FXFP motif.
Ins(1,4,5)P3 3-kinase
Ins(1,4,5)P3  3-kinase catalyzes the formation of
Ins(1,3,4,5)P4  from Ins(1,4,5)P3. Three forms of
Ins(1,4,5)P3 3-kinase have been cloned; these forms differ
in their molecular mass, regulation by Ca2/calmodulin,
tissue distribution and intracellular localization [57-64].
All three forms of human (Tables 1 and 2) and both forms
of mouse (Table 4) Ins(1,4,5)P3 3-kinase contain one or
more optimal sequence for MAPK phosphorylation.
Human Ins(1,4,5)P3 3-kinase B contains both an FXFP
motif and a D-domain, whereas the A and C isoforms do
not contain either of these two MAPK docking sequences
(Tables 1 and 2). Ins(1,4,5)P3 3-kinase B, which plays a
critical role in T-cell development [65,66], is associated
with the endoplasmic reticulum via its N-terminus
[57,67]. Thus, it is possible that the MAPK binding to the
56FLFP sequence motif and/or phosphorylation of serine-
71 within the optimal phosphorylation sequences
(69PRSP) regulates Ins(1,4,5)P3  3-kinase B interaction
with the endoplasmic reticulum.
Ins(1,3,4)P3 5/6-kinase/Ins(3,4,5,6) 1-kinase
Wilson and Majerus [68] cloned an Ins(1,3,4)P3  5/6-
kinase, which was subsequently shown by Yang and
Shears [69] to be the same as Ins(3,4,5,6)P4 1-kinase.
Interestingly, this enzyme also possesses Ins(1,3,4,5,6)P5
1-phosphatase activity [70]. Regulation of these latter two
reciprocal activities provides a mechanism for tight con-
trol of Ins(3,4,5,6)P4 levels in cells. The production of
Ins(1,3,4,6)P4 by Ins(1,3,4)P3 5/6-kinase is the rate-limit-
ing step in the synthesis of inositol hexakisphosphate
from Ins(1,3,4)P3 [71]. We were unable to identify an
optimal sequence for MAPK phosphorylation, an FXFP
motif or a D-domain in human (Table 2) or mouse (Table
4) Ins(1,3,4)P3 5/6-kinase/Ins(3,4,5,6) 1-kinase.Cell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
Page 10 of 18
(page number not for citation purposes)
Inositol polyphosphate multikinase/Ins(1,3,4,6)P4 5-kinase
Inositol polyphosphate multikinase catalyzes the forma-
tion of Ins(1,3,4,5,6)P5 from Ins(1,4,5)P3 by phosphor-
ylation of both the 3- and 6-position of the inositol ring
[30,36], with phosphorylation of the 3-position possibly
preceding that of the 6-position [72]. The enzyme also
phosphorylates the 1-position of Ins(4,5)P2  to form
Ins(1,4,5)P3 [72]. Majerus and colleagues [73] reported
that  in vitro the enzyme displays specificity as an
Ins(1,3,4,6) 5-kinase. Neither the human (Table 2) nor
mouse (Table 4) protein contains an FXFP motif, a D-
domain or optimal sequence for MAPK phosphorylation.
Ins(1,3,4,5,6) 2-kinase
Ins(1,3,4,5,6)P2 2-kinase catalyzes the final step in the
synthesis of inositol hexakisphosphate from Ins(1,3,4)P3,
and ultimately from Ins(1,4,5)P3 [71]. The human 2-
kinase contains an FXFP motif, but does not contain a D-
domain (Table 1). We did not identify an optimal
sequence for MAPK phosphorylation.
Inositol monophosphatase
Inositol monophosphatase is a Mg2+-dependent enzyme
that catalyzes the hydrolysis of Ins1P, Ins3P and Ins4P, as
well as several related compounds, but does not hydrolyze
Ins2P [74-78]. Inositol monophosphatase has received
significant attention as a potential site of action for lith-
ium in the treatment of bipolar disorder. However, recent
studies have identified a number of other lithium targets,
as well [79].
Three forms of inositol monophosphatase have been
identified: A1 (IMPA1), A2 (IMPA2) and A3 (IMPA3). Of
these three forms, only inositol monophosphatase A1
contains an identifiable D-domain (Tables 6 and 8). The
human and mouse sequences differ by two amino acids in
this region resulting in an alternative pair of D-domains in
the mouse isoform (and 261RIAKEIEI and 261RIAKEIEIIPL)
and a single D-domain in the human isoform
(261RIAKEIQVIPL). We did not find an optimal sequence
for MAPK-catalyzed phosphorylation or an FXFP motif in
Table 7: Phosphatases (human) that do not have an FXFP motif and/or D-domain sequence. Phosphatases that use 
phosphatidylinositols or inositols as substrates and do not contain an FXFP or D-domain sequence are listed in the table; all sequences 
are for human proteins. The number of potential MAPK phosphorylation sites and sequences fitting the optimal MAPK 
phosphorylation in these kinases are also identified.
Isozyme GenBank Accession # # amino acids # (S/T)P sites Site(s) with the consensus 
PX(S/T)P sequence
inositol monophosphatase A2 NP_055029 288 1 none
inositol monophosphatase A3 NP_060283 359 3 none
Myotubularin; MTM1 Q13496 603 3 586PTSP
589PSSP
Myotubularin-related protein 2; MTMR2 Q13614 643 4 none
Myotubularin-related protein 3; MTMR3 Q13615 1198 9 582PTTP
Myotubularin-related protein 6; MTMR6 Q9Y217 621 3 559PESP
Inositol polyphosphate 4-phosphatase, Type II NP_003857 924 7 485PPSP
Inositol 1,4,5-trisphosphate 5-phosphatase, Type I Q14642 412 3 none
Synaptojanin 1 (synaptic inositol 1,4,5-trisphosphate 5-
phosphatase 1)
O43426 1575 23 1090PATP
1148PPSP
1161PKSP
Sac-domain-containing inositol phosphatase 2 isoform 2; 
inositol polyphosphate 5-phosphatase F isoform 2
NP_938144 500 8 none
Sac-domain-containing inositol phosphatase 2 isoform 3; 
inositol polyphosphate 5-phosphatase F isoform 3
NP_938145 219 1 none
PI(4,5)P2 5-phosphatase A; PIB5PA; PIPP Q15735 1006 26 148PRSP
199PSTP
345PRSP
Skeletal muscle and kidney enriched inositol phosphatase 
isoform 1; SKIP 1
NP_057616 448 4 283PDTP
356PSSP
Skeletal muscle and kidney enriched inositol phosphatase 
isoform 2; SKIP 2
NP_570122 372 4 207PDTP
280PSSP
Phospholipids-inositol phosphatase; PTEN-like phosphatase; 
PLIP; PTPM1
AAH20242 201 1 none
Inositol polyphosphate 5-phosphatase 2; SH2-containing 
inositol 5'-phosphatase 2; SHIP2
JC5765 1258 7 156PSSP
163PETP
956PLTP
1001PPSPCell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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any of the human or mouse inositol monophosphatase
isozymes.
1-phosphatase
Inositol polyphosphate 1-phosphatase is a Mg2+-depend-
ent enzyme that hydrolyzes Ins(1,4)P2 and Ins(1,3,4)P3,
and is inhibited by lithium [76,80-82]. Similar to inositol
monophosphatase, the 1-phosphatase has received atten-
tion as a site of therapeutic action for lithium in the treat-
ment of bipolar disorder [83]. Notably, the human (Table
6), but not the mouse (Table 9), 1-phosphatase contains
a D-domain. Neither the human nor mouse enzyme con-
tains an FXFP motif or an optimal sequence for MAPK
phosphorylation.
3-phosphatase
Myotubularin, which was originally identified as a candi-
date gene mutated in X-linked myotubular myopathy
[84], has been shown to possess PtdIns3P 3-phosphatase
activity [85,86]. A number of myotubularin-related
(MTMR) proteins have also been identified [87,88]. Myo-
tubularin (also called MTM1), MTMR1, MTMR2, MTMR3,
and MTMR6 possess PtdInd(3)P 3-phosphatase activity
[89]. In addition to their PtdIns3P 3-phosphatase activity,
myotubularin, [90], MTMR2 [91], MTMR3 [92], and
MTMR6 [90] also possess PtdIns(3,5)P2 3-phosphatase
activity; however, it should be noted that Kim et al. [89]
reported that myotubularin and MTMR2 do not hydro-
lyze PtdIns(3,5)2. Additionally, myotubularin and
MTMR2 have been shown to hydrolyze Ins(1,3)P2 [89].
When we analyzed the human (Table 7) and mouse
(Table 9) myotubularin protein sequences, we did not
find either an FXFP or D-domain sequence. However, the
human sequence does contain two optimal MAPK phos-
phorylation sequences not present in the mouse
sequence. We identified a conserved D-domain in the
human (Table 6) and mouse (Table 8) MTMR1 protein,
but did not find an optimal sequence for MAPK phospho-
rylation or FXFP motif in either protein. Neither the
human (Table 7) nor the mouse (Table 9) MTMR2 has an
optimal sequence for MAPK phosphorylation, a D-
doman, or an FXFP motif. Although the human (Table 7)
and mouse (Table 9) MTMR3 and MTMR6 each contain a
sequence fitting the optimal sequence for MAPK phos-
phorylation, they do not contain an identifiable D-
domain or FXFP motif.
PTEN (phosphatase and tensin homologue deleted on
chromosome 10) is a PtdIns(3,4,5)P3 3-phosphatase [93],
as well as Ins(1,3,4,5)P4  3-phosphatase [93] and
Ins(1,3,4,5,6)P5 3-phosphatase [94]. The human (Table
6) and mouse (Table 8) PTEN sequences contain a con-
served FXFP sequence, but no identifiable D-domain or
optimal MAPK phosphorylation sequence.
4-phosphatase
Two forms (Types I and II) of inositol polyphosphate 4-
phosphatase have been identified [95-97]. These enzymes
cleave the 4-phosphate from Ins(1,3,4)P2, Ins (3,4)P2,
and PtdIns(3,4)P2. The Type I 4-phosphatase has been
reported to localize to endosomes, where it plays an
important role in the generation of PtdIns3P [98]. In
growth factor-stimulated cells the Type I 4-phosphatase
also localizes to plasma membrane ruffles, where it
hydrolyzes PtdIns(3,4,)P2, thereby regulating the associa-
tion of PtdIns(3,4)P2-binindg proteins with the plasma
membrane [98]. We identified a conserved D-domain in
human (Table 6) and mouse (Table 8) Type I 4-phos-
phatase. However, we did not identify an optimal phos-
phorylation sequence or an FXFP motif in this isoform. In
contrast, we did not identify a D-domain in the human
Type II 4-phosphatase (Table 7), although it does contain
a consensus MAPK phosphorylation site. Human Type II
4-phosphatase also does not contain an FXFP motif.
The Sac phosphatase domain, a region of sequence
homology found in several yeast, plant and animal pro-
teins, can hydrolyze the 3-, 4-, or 5-position phosphate
from PIs, although vicinal phosphate groups are resistant
to hydrolysis [99,100]; thus, PtdIns3P, PtdIns4P and
PtdIns(3,5)P2 are substrates, whereas PtdIns(4,5)P2 is not.
The PtdIns4P phosphatase activity, but not PtdIns3P or
PtdIns(3,5)P2 phosphatase activities, of mammalian Sac1
complements phenotypic defects observed in yeast having
deletions of Sac1p [101], indicating that the 4-phos-
phatase activity of these proteins is the most important in
vivo. The human (Table 6) and mouse (Table 8) Sac1 pro-
teins each contain five identifiable D-domains. Two of
these D-domains are overlapping sequences
(345KNMRWDRLSI and 348RWDRLSILL) and two are an
alternative pair of D-domains (517RDWKFLAL and
517RDWKFLALPI). Neither the human nor mouse protein
contains an optimal phosphorylation site for MAPKs or
an FXFP motif.
5-phosphatase
The inositol polyphosphate 5-phosphatases are com-
monly classified on the basis of their substrate specificities
[27,50]. In this system of classification, the Group I
enzymes hydrolyze the water-soluble compounds
Ins(1,4,5)P3 and Ins(1,3,4,5)P4; the Group II enzymes
hydrolyze both water-soluble and lipid substrates (e.g.,
PtdIns(4,5,)P2  and PtdIns(3,4,5)P3); the Group III
enzymes hydrolyze the 3-phosphate-containing com-
pounds, Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; and, the sin-
gle Group IV enzyme hydrolyzes only the lipid substrates
PtdIns(3,4,5)P3 and PtdIns(4,5)P2 [27,102]. Although we
have used this classification system, we note that recent
studies have demonstrated that the substrate specificities
of several of the identified 5-phosphatases do not fit intoCell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
Page 12 of 18
(page number not for citation purposes)
this simple system [103,104]. For example, Schmid et al
[103] have shown that there are significant differences in
the substrate specificities of several "Type II" 5-phos-
phatases: synaptojannin 1, synaptojanin 2, the gene prod-
uct responsible for Lowe's oculocerebrorenal syndrome
(OCRL), skeletal muscle and kidney enriched phos-
phatase (SKIP), and INPP5B. Additionally, it should be
noted that the in vitro and in vivo specificities of these
enzymes may differ.
We did not identify a D-domain, FXFP motif or optimal
MAPK phosphorylation sequence in either the human
(Table 7) or mouse (Table 9) Type I 5-phosphatase. Sev-
eral of the Group II 5-phosphatases (Tables 6 and 8) con-
tain an identifiable D-domain. OCRL is the gene
responsible for occulocerebrorenal dystrophy or Lowe's
syndrome, when mutated [27]. Both the human (Table 6)
and mouse (Table 8) OCRL proteins contain a D-domain,
but do not contain an FXFP motif or an optimal sequence
for MAPK phosphorylation. Synaptojanin 1 and synapto-
janin 2 are neuronal proteins that play a role in synaptic
vesicle trafficking. They contain both a 5-phosphatase
domain and a Sac phosphatase domain [99]. The 5-phos-
phatase domain is responsible for the reported
PtdIns(4,5)P2-hydrolyzing activity of synaptojanins,
while the Sac domain of synaptojanins accounts for their
Table 8: Phosphatases (mouse) that have an FXFP motif and/or D-domain sequence. The number of potential MAPK phosphorylation 
sites, sequences fitting the optimal MAPK phosphorylation consensus sequence of PX(S/T)P, and FXFP motifs and D-domain 
sequences in phosphatases that use phosphatidylinositols or inositols as substrates are listed in the table; all sequences are for mouse 
proteins.
Isozyme GenBank 
Accession #
# amino 
acids
# (S/T)P sites Site(s) with the 
consensus PX(S/
T)P sequence
FXFP motif D-domain motif
monophosphatase
inositol monophosphatase A1 O55023 277 2 none none 261RIAKEIEI
261RIAKEIEIIPL
3-phosphatase
Myotubularin-related protein 1; MTMR1 NP_058681 669 4 none none 181KDMRNLRL
PI(3,4,5)P3 3-phosphatase, PTEN O08586 403 2 none 241FEFP none
4-phosphatase
Inositol polyphosphate 4-phosphatase, Type Ia NP_084542 939 7 none none 147RHHRLHLTL
SAC1 poly-phosphatidylinositol phosphatase CAC20672 587 3 none none 345KNMRWDRLSI
348RWDRLSILL
461RTGKRTQLGL
517RDWKFLAL
517RDWKFLALPI
5-phosphatase
Group II
Inositol polyphosphate 5-phosphatase OCRL NP_796189 900 2 none none 445KLLKFDGLNI
Synaptojanin 2 (synaptic inositol 1,4,5-
trisphosphate 5-phosphatase 2)
Q9D2G5 1434 15 987PVSP none 617RSHRYILL
Sac-domain-containing inositol phosphatase 3 NP_598760 907 5 none none 663KFHRWEEEIDI
Inositol polyphosphate 5-phosphatase, 75 kDa; 
Inositol polyphosphate 5-phosphatase B
NP_032411 993 5 none none 31RQSRLLGL
420KFVRLVGIML
Group III
Inositol polyphosphate 5-phosphatase, 145 kDa; 
inositol polyphosphate 5-phosphatase D; SH2-
containing inositol 5'-phosphatase 1; SHIP1
NP_034696 1191 12 962PPTP
970PLSP
none 352KSQKFLNKLVI
Group IV
PI polyphosphate 5-phosphatase type IV; 
Inositol polyphosphate 5-phosphatase E
Q9JII1 647 7 243PRSP none 83KLERTLSL
599RPGRDNIPL
611KFDRELYL
611KFDRELYLIGICell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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ability to also hydrolyze other PIs, such as the PtdIns4P
product generated by the action of its 5-phosphatase
domain [105]. Both synaptojanin 1 and 2 contain opti-
mal phosphorylation sites for MAPKs. However, only syn-
aptojanin 2 contains a D-domain, which is conserved in
the human (Table 6) and mouse (Table 8) proteins. The
synaptojanin sequences that we searched do not contain
an FXFP motif. The human (Table 6) and mouse (Table 8)
75-kDa inositol polyphosphate 5-phosphatases (inositol
polyphosphate 5-phosphatase B) contain two conserved
D-domains, but are devoid of an FXFP motif and an opti-
mal sequence for MAPK phosphorylation.
The Group III SH2-containing inositol 5'-phosphatase 1
(SHIP1) is a hematopoietic-specific enzyme that hydro-
lyzes both PtdIns(3,4,5)3  and Ins(1,3,4,5)P4  [106]. In
addition, SHIP1 is able to hydrolyze the 4-phosphate
from PtdIns(4,5) in vitro, thereby generating PtdIns5P
[107]. The human (Table 6) and mouse (Table 8) SHIP1
contain an identifiable D-domain. The human SHIP1
contains four optimal MAPK phosphorylation sequences;
corresponding sequences for two of these are present in
the mouse protein, whereas two are unique to the human
protein. SHIP1 does not contain a sequence conforming
to an FXFP motif. The distribution of SHIP2 is more ubiq-
uitous than is that of SHIP1 [106]. The human SHIP2 is
devoid of a D-domain or an FXFP motif (Table 7). It does
contain four sequences that fit the optimal phosphoryla-
tion sequence for a MAPK. The human (Table 6) and
mouse (Table 8) Group IV 5-phosphatase contain a con-
served optimal sequence (PRSP) for MAPK phosphoryla-
tion; the human protein contains an additional optimal
sequence of MAPK phosphorylation (55PATP). Both the
human and mouse Group IV 5-phosphatase contain an
alternative pair of D-domains, as well as two other D-
domains; neither contains an FXFP motif.
Additional sequence analyses
We examined each of the D-domains that we identified to
determine if it overlaps with a KIM [14] or fits the MAPK-
docking site consensus sequence defined by Bardwell and
colleagues [15,16]. We found only one instance of overlap
with a KIM: in the human PI 4-kinase α, the sequence
12LDERRRDAVIALGI not only contains the alternative
pair of D-domains that we identified (Table 1), but also
contains a KIM. Examination of the sequences found in
Tables 1, 3, 6, and 8 revealed that, in several instances, the
D-domain sequence fits the MAPK-docking sequence of
Bardwell and colleagues. It should be noted that in several
proteins we identified, but did not catalog, one or more
sequence that conformed to the MAPK-docking motif of
Bardwell and colleagues but did not conform to the more
restrictive sequence that we used for a D-domain.
Finally, we also analyzed the sequences of PtdIns synthase
(CDP-1,2-diacyl-sn-glycerol:myo-inositol 3-phosphatidyl-
transferase) isozymes, which catalyze the production of
PtdIns from cytidine diphosphodiacylglycerol and myo-
inositol. We did not identify either an FXFP or a D-
domain sequence in human or mouse PtdIns synthase
sequences (GenBank:NP_006310, NP_665695, and
NP_620093; data not shown). Further, we identified a
MAPK phosphorylation site only in the human isoform 2.
These results indicate that the isozymes that catalyze
PtdIns synthesis are not likely to be directly regulated by
MAPK; however, they do not rule out the possibility that
MAPKs may control PtdIns synthesis via an effect on myo-
inositol (e.g., via an effect on inositol monophosphatase
A1) or cytidine diphosphodiacylglycerol levels.
Conclusion
We found a high degree of conservation of D-domain
sequence and location in human and mouse proteins.
Notable exceptions were PI 3-kinase C2-γ, PI 4-kinase type
IIβ, and inositol polyphosphate 1-phosphatase. For each
of these proteins, either the human or mouse protein con-
tained one or more D-domains that were not found in the
other, with the differences in PI 3-kinase C2-γ being the
most striking.
Other than within subtypes of an isozyme, we found no
evidence of sequence conservation of D-domains in
enzymes that metabolize PIs and IPs. That is, the primary
sequences of the D-domains that we found were quite var-
iable. This indicates that, both within a family and across
families of these enzymes, there may be specificity for
binding interactions with MAPKs. Detailed studies exam-
ining the relative specificities of each of these proteins for
individual MAPKs, if they indeed bind MAPKs, and the
contribution of individual amino acids within these
sequences to MAPK binding, will provide important infor-
mation for the development of tools aimed at modifying
the integration of MAPK and signaling via PIs and IPs.
When D-domains were found in more than one location
in a protein, each D-domain had a unique sequence. This
is noted because it is not a universal property of protein-
protein interaction domains when present in multiples in
a protein- e.g., an SH2-binding motif is commonly present
in multiple copies in docking proteins [108]. Within a
protein, it is possible that each D-domain binds a unique
MAPK, or set of MAPKs, allowing for interaction with
more than one MAPK signaling pathway, and, thus, the
regulation of the metabolism of a particular PI/IP by vari-
ous combinations of stimuli, or the formation of differing
combinations of signaling complexes allowing for the
generation of various downstream signals. Further, it is
also possible that each interaction is independently regu-
lated. Therefore, it is reasonable to think that these D-Cell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
Page 14 of 18
(page number not for citation purposes)
domains do not simply serve to amplify signaling through
a single signaling pathway, but, instead, allow for the inte-
gration of multiple MAPK pathways with the metabolism
of a specific PI or IP.
The frequency of occurrence of an identifiable FXFP motif
in the enzymes that we analyzed was significantly less
than that of a D-domain. There were only five enzymes in
which we found a motif conforming to the sequence
FXFP; four of these were in kinases (PI 3-kinase δ, PI 4-
kinase α, Ins(1,4,5)P3 3-kinase B, and Ins(1,3,4,5,6) 2-
kinase) and only a single one was found in a phosphatase
(PTEN). It is noteworthy that of all the enzymes that we
analyzed, only PI 4-kinase α and Ins(1,4,5)P3 3-kinase B
contain both a D-domain and an FXFP sequence. Finally,
we found several sequences fitting an FXF motif (data not
shown). As noted in the Introduction, the FXF sequence
has been reported to be sufficient for MAPK binding, indi-
cating that these sites may also bind MAPKs.
At this time, we can only speculate on the physiologic sig-
nificance of the presence of MAPK binding domains in
enzymes that control the metabolism of PIs and IPs. We
have previously shown that phospho-ERK2-dependent
phosphorylation of PLC-γ1 opposes tyrosine kinase-
dependent activation of PLC-γ1 [25]. Similarly, MAPKs
may regulate (either stimulating or inhibiting) the cata-
lytic activity, or specificity, of kinases and phosphatases
that are involved in the metabolism of PIs or IPs, and
thereby exert regulatory actions on PI- and/or IP-depend-
ent signaling pathways. Intriguing possibilities exist when
a kinase and phosphatase are present in the same complex
and one or both of them bind a MAPK. For example, the
p85 subunit of Class I PI 3-kinase has been reported to
form a complex with Type I inositol polyphosphate 4-
phosphatase [109], SHIP1 5-phosphatase [110], and Type
IV 5-phosphatase [111]. In these complexes, MAPKs may
regulate the relative level or turnover of the substrates and
products; for example, by enhancing PI3-kinase activity
and associated SHIP1 (or Type IV) 5-phosphatase activity,
it would be possible to increase PtdIns(3,4)P2 levels with-
out increasing PtdIns(3,4,5)P3  levels. Other scenarios
(e.g., delayed activation kinetics of the associated 5-phos-
phatase) are also imaginable, resulting in a transient rise
in PtdIns(3,4,5)P3  with a delayed elevation in
PtdIns(3,4,)P2 levels. Similarly, complexes of the Type I
inositol polyphosphate 4-phosphatase and PI 3-kinase
could produce locally elevated levels of PtdIns3P, without
elevating PtdIns(3,4)P2 levels, or elevate PtdIns(3,4)P2
and, with a delay, PtdIns3P. It is also possible that the
interaction between a MAPK and a PI/IP kinase or phos-
phatase may recruit the MAPK to a multimolecular signal
transduction complex containing components of path-
ways that regulate the activity of the MAPK (e.g., binding
of a MAPK to PI 3-kinase may act to recruit the MAPK to a
growth factor signaling complex containing Ras and a
MAPK kinase) or target the MAPK to a particular subcellu-
lar localization (e.g., binding to Type I inositol polyphos-
phate 4-phosphatase may act to target the MAPK to
endosomes).
Table 9: Phosphatases (mouse) that do not have an FXFP motif and/or D-domain sequence. Phosphatases that use 
phosphatidylinositols or inositols as substrates and do not contain an FXFP or D-domain sequence are listed in the table; all sequences 
are for mouse proteins. The number of potential MAPK phosphorylation sites and sequences fitting the optimal MAPK 
phosphorylation in these kinases are also identified.
Isozyme GenBank Accession # # amino acids # (S/T)P sites Site(s) with the consensus 
PX(S/T)P sequence
inositol monophosphatase A2 NP_444491 290 1 none
inositol monophosphatase A3 NP_808398 356 2 none
Inositol polyphosphate 1-phosphatase P49442 396 2 none
Myotubularin; MTM1 Q9Z2C5 603 1 none
Myotubularin-related protein 2; MTMR2; Q9Z2D1 (AAH63050)6 4 3 4 n o n e
Myotubularin-related protein 3; MTMR3 CAI35186 1159 7 582PSTP
Myotubularin-related protein 6; MTMR6 NP_659092 617 3 555PETP
Inositol polyphosphate 4-phosphatase, Type Ib (variant) NP_766559 679 3 none
Inositol 1,4,5-trisphosphate 5-phosphatase, Type I AAH56341 412 2 none
Synaptojanin 1 (synaptic inositol 1,4,5-trisphosphate 5-
phosphatase 1)
Q8CHC4 1574 19 1145PPSP
1158PKSP
1443PNSP
PI(4,5)P2 5-phosphatase A; PIB5PA; PIPP NP_766027 1003 31 197PQSP
200PSSP
346PRSP
Skeletal muscle and kidney enriched inositol phosphatase 
isoform 1; SKIP 1
Q8C5L6 468 5 none
Phospholipid-inositol phosphatase; PTEN-like phosphatase; 
PLIP
NP_079852 261 3 noneCell Communication and Signaling 2006, 4:2 http://www.biosignaling.com/content/4/1/2
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It should be noted that a protein can serve as a MAPK sub-
strate without directly binding the MAPK: c-Jun-bound
proteins that lack a JNK binding site can be phosphor-
ylated by JNK [112]. Thus, our inability to identify a
MAPK binding site in a protein does not preclude it from
being a MAPK substrate. For example, the MAPK optimal
phosphorylation site identified in Type IIα PIPK could be
phosphorylated by a MAPK bound to Type Iα PIPK, which
has been shown to co-immunoprecipitate with Type IIα
PIPK [113]. Similarly, although we did not identify a D-
domain or FXFP motif in the 3-phosphatase myotubu-
larin, it may be a MAPK substrate when bound to the 3-
phosphatase adaptor protein (3-PAP) subunit [114],
which has four recognizable D-domains (data not
shown). In fact, human myotubularin does contain two
optimal MAPK phosphorylation sequences (Table 7),
indicating that it may be a MAPK substrate.
PI 3-kinase, Ins(1,4,5)P3 3-kinase B, SHIP1 and PTEN
have each been proposed to regulate MAPK signaling. In
the case of PI 3-kinase, several studies have been pub-
lished showing that wortmannin and/or LY-294002,
which are inhibitors of PI 3-kinase catalytic activity, block
the activation of MAPKs by various stimuli. However, to
our knowledge, a direct interaction between a PI 3-kinase
and a MAPK has not been demonstrated, and the mecha-
nisms underlying the apparent PI 3-kinase-dependent reg-
ulation of MAPKs remain speculative. In the case of PI 3-
kinase γ, the effect could be mediated by MEK-1, a MAPK
kinase which has been shown to be an in vitro substrate of
PI 3-kinase γ [115]. Wen et al [65] have shown that ERK1/
2 activation in response to suboptimal stimulation of thy-
mocytes is dependent on Ins(1,4,5)P3 3-kinase B; they
propose a model in which Ins(1,4,5)P3  3-kinase B-
dependent production of Ins(1,3,4,5)P4 acts to sequester
an Ins(1,3,4,5)P4-binding GTPase-activating protein 1
[116], promoting Ras-dependent activation of ERK1/2.
SHIP1, which contains an identifiable D-domain, but no
FXFP motif, has been shown to be a negative regulator of
JNK activation in B cells [117], ERK1/2 activation in the
erythropoietin-dependent cell lineAS-E2 [118], and
MAPK (ERK1/2, JNK and p38) activation in RAW264.7
macrophages [119]. In the latter case, the action was
shown to be independent of the SHIP1 5-phosphatase
activity [119].
Interestingly, SHIP2, which does not have an identifiable
D-domain or FXFP motif, has been reported to not exert
an effect on cellular MAPKs [120,121]. PTEN, which does
not contain a D-domain sequence but does contain an
FXFP motif, has been reported to inhibit insulin-stimu-
lated ERK1/2 activation in MCF-7 epithelial breast cancer
cells [122,123]. Weng et al. [122] concluded that the effect
of PTEN is the result of PTEN-dependent dephosphoryla-
tion of the insulin receptor substrate 1, and consequent
coupling to ERK1/2 activation. In contrast to the studies
of Eng and colleagues, Tang et al. [121] reported that short
interfering RNA-induced reductions of PTEN expression
in 3T3-L1 adipocytes did not affect insulin-dependent sig-
naling to ERK1/2.
In conclusion, there appear to be a plethora of potential
sites of crosstalk between MAPK signaling pathways and
the enzymes controlling cellular PIs and IPs, and, thus, the
signaling pathways that are regulated by the levels of these
intracellular signals. We hope that the identification of
these sites of signal integration will initiate a series of
studies aimed at determining whether these interactions
occur in vivo and the physiologic relevance of each to cel-
lular responding.
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